Analyst Reco. Precigen, Inc.

Equities

PGEN

US74017N1054

Market Closed - Nasdaq Other stock markets 21:00:00 02/05/2024 BST			5-day change	1st Jan Change
1.4 ^USD	0.00%		-1.41%	+4.48%

04-24	Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy	CI
03-25	North American Morning Briefing : Tech in Focus on -2-	DJ

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precigen Shares Fall After Downgrade From JPMorgan	03-22	MT
JPMorgan Downgrades Precigen to Underweight From Neutral	03-22	MT
JPMorgan Initiates Precigen at Neutral Rating	23/05/23	MT
Cantor Fitzgerald Adjusts Price Target on Precigen to $10 From $7, Maintains Overweight Rating	30/01/23	MT
Cantor Fitzgerald Starts Precigen at Overweight With $7 Price Target	18/11/22	MT
HC Wainwright Adjusts Precigen's Price Target to $6 from $10, Keeps Buy Rating	09/08/22	MT
PRECIGEN : B. Riley Raises Precigen's Price Target to $14 from $10, Keeps Buy Rating	02/03/21	MT
PRECIGEN : Stifel Initiates Coverage on Precigen With Buy Rating, Sets Price Target at $13	25/02/21	MT
PRECIGEN : Wells Fargo Starts Precigen at Overweight With $14 Price Target	22/02/21	MT
PRECIGEN : B. Riley Starts Precigen at Buy with $10 Price Target	18/02/21	MT
PRECIGEN : HC Wainwright Adjusts Precigen's Price Target to $10 From $8, Keeps at Buy	16/12/20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer